Stock Market News2 months BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer’s Heart Drug Investor's Business Daily
BridgeBio Pharma snagged FDA approval for its rival to Pfizer’s heart disease treatment, Vyndaqel. BridgeBio stock catapulted.
The post BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug appeared first on Investor…